Amal Tanagho
Huntington Beach, CANPI 1154538023
Payments from drug & device makers
Across 525 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$997
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$881
- Bausch Health US, LLC$703
- plus $3K from 23 others
What the payments were for
- Food & beverage$10,953100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 119 | $2,269 |
| Takeda Pharmaceuticals U.S.A., Inc. | 62 | $1,449 |
| Lundbeck LLC | 47 | $1,173 |
| Otsuka America Pharmaceutical, Inc. | 47 | $997 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $881 |
| Bausch Health US, LLC | 37 | $703 |
| Ironshore Pharmaceuticals Inc. | 27 | $509 |
| Supernus Pharmaceuticals, Inc. | 18 | $343 |
| Axsome Therapeutics, Inc. | 18 | $340 |
| Adlon Therapeutics L.p. | 16 | $304 |
| Vanda Pharmaceuticals Inc. | 13 | $296 |
| Idorsia Pharmaceuticals US Inc | 14 | $257 |
| Alkermes, Inc. | 11 | $251 |
| Eisai Inc. | 13 | $240 |
| Corium, LLC | 9 | $240 |
| Tris Pharma Inc | 8 | $159 |
| Indivior Inc. | 6 | $129 |
| Noven Therapeutics, LLC | 4 | $79 |
| Johnson & Johnson | 3 | $73 |
| Neos Therapeutics, LP | 4 | $69 |
| Collegium Pharmaceutical, Inc. | 2 | $36 |
| Vertical Pharmaceuticals, LLC | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $22 |
| Noven Pharmaceuticals, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Orexo US, Inc. | 1 | $15 |
| MDD US Operations, LLC | 1 | $11 |
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 28 | $8,246 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,028 |
| XanaxAlprazolam | 11 | $2,949 |
| Bupropion XlBupropion Hcl | 119 | $1,754 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 62 | $1,701 |
| Aripiprazole | 58 | $1,083 |
| Clonazepam | 119 | $979 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $735 |
| Duloxetine Hcl | 41 | $688 |
| Trazodone Hcl | 128 | $570 |
| Lamotrigine | 34 | $500 |
| Fluoxetine Hcl | 122 | $392 |
| Alprazolam | 67 | $392 |
| Eszopiclone | 19 | $389 |
| Quetiapine Fumarate | 40 | $331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,449 | $6,02813 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $13420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.